{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:05:28Z","timestamp":1781651128913,"version":"3.54.5"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Recombination activating genes (<jats:italic>RAG<\/jats:italic>) 1 and 2 defects are the most frequent form of severe combined immunodeficiency (SCID). Patients with residual RAG activity have a spectrum of clinical manifestations ranging from Omenn syndrome to delayed-onset combined immunodeficiency, often associated with granulomas and\/or autoimmunity (CID-G\/AI). Lentiviral vector (LV) gene therapy (GT) has been proposed as an alternative treatment to the standard hematopoietic stem cell transplant and a clinical trial for RAG1 SCID patients recently started. However, GT in patients with hypomorphic RAG mutations poses additional risks, because of the residual endogenous RAG1 expression and the general state of immune dysregulation and associated inflammation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, we assessed the efficacy of GT in 2 hypomorphic Rag1 murine models (Rag1<jats:sup>F971L\/F971L<\/jats:sup> and Rag1<jats:sup>R972Q\/R972Q<\/jats:sup>), exploiting the same LV used in the clinical trial encoding RAG1 under control of the MND promoter.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results and discussion<\/jats:title><jats:p>Starting 6 weeks after transplant, GT-treated mice showed a decrease in proportion of myeloid cells and a concomitant increase of B, T and total white blood cells. However, counts remained lower than in mice transplanted with WT Lin- cells. At euthanasia, we observed a general redistribution of immune subsets in tissues, with the appearance of mature recirculating B cells in the bone marrow. In the thymus, we demonstrated correction of the block at double negative stage, with a modest improvement in the cortical\/medullary ratio. Analysis of antigenspecific IgM and IgG serum levels after <jats:italic>in vivo<\/jats:italic> challenge showed an amelioration of antibody responses, suggesting that the partial immune correction could confer a clinical benefit. Notably, no overt signs of autoimmunity were detected, with B-cell activating factor decreasing to normal levels and autoantibodies remaining stable after GT. On the other hand, thymic enlargement was frequently observed, although not due to vector integration and insertional mutagenesis. In conclusion, our work shows that GT could partially alleviate the combined immunodeficiency of hypomorphic RAG1 patients and that extensive efficacy and safety studies with alternative models are required before commencing RAG gene therapy in thesehighly complex patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1268620","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T02:06:29Z","timestamp":1699927589000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Partial correction of immunodeficiency by lentiviral vector gene therapy in mouse models carrying Rag1 hypomorphic mutations"],"prefix":"10.3389","volume":"14","author":[{"given":"Maria Carmina","family":"Castiello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Di Verniere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Draghici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Penna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Sereni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Zecchillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Minuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Uva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Gil-Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Annoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Iaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Ott de Bruin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi D.","family":"Notarangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Pike-Overzet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J. T.","family":"Staal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Capo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/imr.12713","article-title":"RAG gene defects at the verge of immunodeficiency and immune dysregulation","volume":"287","author":"Villa","year":"2019","journal-title":"Immunol Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/EJI.202048880","article-title":"RAG deficiencies: Recent advances in disease pathogenesis and novel therapeutic approaches","volume":"51","author":"Bosticardo","year":"2021","journal-title":"Eur J Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.607926","article-title":"Innovative cell-based therapies and conditioning to cure RAG deficiency","volume":"11","author":"Villa","year":"2020","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1381558","article-title":"Long term outcomes of severe combined immunodeficiency: therapy implications","volume":"13","author":"Heimall","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-840702","article-title":"SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery","volume":"132","author":"Haddad","year":"2018","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2022017667","article-title":"Hypomorphic RAG deficiency: impact of disease burden on survival and thymic recovery argues for early diagnosis and HSCT","volume":"141","author":"Schuetz","year":"2022","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/J.JACI.2021.10.017","article-title":"Hematopoietic cell transplantation in severe combined immunodeficiency: The SCETIDE 2006-2014 European cohort","volume":"149","author":"Lankester","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.10.009","article-title":"Recombination-activating gene 1 (Rag1)-deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome","volume":"133","author":"Van Til","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.106","article-title":"Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer","volume":"25","author":"Pike-Overzet","year":"2011","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.03.016","article-title":"Successful preclinical development of gene therapy for recombinase-activating gene-1-deficient SCID","volume":"17","author":"Garcia-Perez","year":"2020","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0782","article-title":"Gene therapy of RAG-2-\/- mice: Sustained correction of the immunodeficiency","volume":"100","author":"Yates","year":"2002","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.110","article-title":"Correction of murine rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene","volume":"20","author":"Van Til","year":"2012","journal-title":"Mol Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.jaci.2017.11.015","article-title":"Efficacy of lentivirus-mediated gene therapy in an Omenn syndrome recombination-activating gene 2 mouse model is not hindered by inflammation and immune dysregulation","volume":"142","author":"Capo","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B14","unstructured":"LUMCFirst patient in the Netherlands successfully treated with stem cell gene therapy"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-820985","article-title":"Hypomorphic Rag1 mutations alter the preimmune repertoire at early stages of lymphoid development","volume":"132","author":"Ott de Bruin","year":"2018","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1089\/104303401750148649","article-title":"Detection and direct genomic sequencing of multiple rare unknown flanking DNA in highly complex samples","volume":"12","author":"Schmidt","year":"2001","journal-title":"Hum Gene Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/NPROT.2010.87","article-title":"Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing","volume":"5","author":"Paruzynski","year":"2010","journal-title":"Nat Protoc"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2057","article-title":"Comprehensive genomic access to vector integration in clinical gene therapy","volume":"15","author":"Gabriel","year":"2009","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2016.12.001","article-title":"GENE-IS: time-efficient and accurate analysis of viral integration events in large-scale gene therapy data","volume":"6","author":"Afzal","year":"2017","journal-title":"Mol Ther - Nucleic Acids"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/J.1467-9868.2006.00551.X","article-title":"Testing against a high dimensional alternative","volume":"68","author":"Goeman","year":"2006","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2018.02285\/BIBTEX","article-title":"BAFF and BAFF-receptor in B cell selection and survival","volume":"9","author":"Smulski","year":"2018","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","first-page":"227ra33","DOI":"10.1126\/scitranslmed.3007280","article-title":"Gene therapy for Wiskott-Aldrich syndrome-long-term efficacy and genotoxicity","volume":"6","author":"Braun","year":"2014","journal-title":"Sci Transl Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200301163480314","article-title":"A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency","volume":"348","author":"Hacein-Bey-Abina","year":"2003","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/NM1393","article-title":"Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1","volume":"12","author":"Ott","year":"2006","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31659","article-title":"Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy","volume":"117","author":"Deichmann","year":"2007","journal-title":"J Clin Invest"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"N the Journal of Clinical Investigation"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1003548","article-title":"Stem-cell gene therapy for the Wiskott-Aldrich syndrome","volume":"363","author":"Boztug","year":"2010","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"N the Journal of Clinical Investigation"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-28762-2","article-title":"A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders","volume":"13","author":"Tucci","year":"2022","journal-title":"Nat Commun"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2020.608653","article-title":"Immune reconstitution after gene therapy approaches in patients with X-linked severe combined immunodeficiency disease","volume":"11","author":"Blanco","year":"2020","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2019.00782","article-title":"B cell reconstitution and influencing factors after hematopoietic stem cell transplantation in children","volume":"10","author":"Van Der Maas","year":"2019","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1084\/JEM.179.4.1355","article-title":"Two waves of recombinase gene expression in developing thymocytes","volume":"179","author":"Wilson","year":"1994","journal-title":"J Exp Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90131-0","article-title":"Down-regulation of RAG1 and RAG2 gene expression in preB cells after functional immunoglobulin heavy chain rearrangement","volume":"3","author":"Grawunder","year":"1995","journal-title":"Immunity"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2021.659761","article-title":"The interplay between chromatin architecture and lineage-specific transcription factors and the regulation of rag gene expression","volume":"12","author":"Miyazaki","year":"2021","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/S10875-021-00989-6","article-title":"Gene editing rescues in vitro T cell development of RAG2-deficient induced pluripotent stem cells in an artificial thymic organoid system","volume":"41","author":"Gardner","year":"2021","journal-title":"J Clin Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2023.101731","article-title":"Correcting inborn errors of immunity: From viral mediated gene addition to gene editing","volume":"66","author":"Castiello","year":"2023","journal-title":"Semin Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2020010260","article-title":"Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency","volume":"138","author":"Reinhardt","year":"2021","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1700554\/SUPPL_FILE\/NEJMOA1700554_DISCLOSURES.PDF","article-title":"Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N Engl J Med"},{"key":"B41","article-title":"Myelodysplastic syndromes after eli-cel gene therapy for cerebral adrenoleukodystrophy (CALD)","author":"Williams","year":"2022"},{"key":"B42","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/nm.2088","article-title":"Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease","volume":"16","author":"Stein","year":"2010","journal-title":"Nat Med 2010 162"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2016-12-756734","article-title":"Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients","volume":"129","author":"Cooper","year":"2017","journal-title":"Blood"},{"key":"B44","article-title":"Retroviral gene therapy for the treatment of ADA-SCID: long-term follow up and first case of T-cell acute leukaemia due to insertional mutagenesis","volume":"5","author":"Cicalese","year":"2021","journal-title":"HemaSphere"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2005-08-024976","article-title":"Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity","volume":"108","author":"Modlich","year":"2006","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/J.YMTHE.2021.06.017","article-title":"Predicting genotoxicity of viral vectors for stem cell gene therapy using gene expression-based machine learning","volume":"29","author":"Schwarzer","year":"2021","journal-title":"Mol Ther"},{"key":"B47","doi-asserted-by":"publisher","first-page":"eade0182","DOI":"10.1126\/sciimmunol.ade0182","article-title":"Single-cell immune profiling reveals thymus-seeding populations, T cell commitment, and multilineage development in the human thymus","volume":"7","author":"Cordes","year":"2022","journal-title":"Sci Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1084\/JEM.20042524","article-title":"New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling","volume":"201","author":"Dik","year":"2005","journal-title":"J Exp Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.04.033","article-title":"Successful RAG1-SCID gene therapy depends on the level of RAG1 expression","volume":"134","author":"Pike-Overzet","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/NATURE13317","article-title":"Cell competition is a tumour suppressor mechanism in the thymus","volume":"509","author":"Martins","year":"2014","journal-title":"Nature"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/J.OMTN.2016.11.011","article-title":"Limiting thymic precursor supply increases the risk of lymphoid Malignancy in murine X-linked severe combined immunodeficiency","volume":"6","author":"Ginn","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"B52","doi-asserted-by":"publisher","first-page":"eaan0820","DOI":"10.1126\/scitranslmed.aan0820","article-title":"Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1","volume":"9","author":"Schiroli","year":"2017","journal-title":"Sci Transl Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-018-0537-4","article-title":"RAG deficiency: two genes, many diseases","volume":"38","author":"Delmonte","year":"2018","journal-title":"J Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1268620\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T02:06:45Z","timestamp":1699927605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1268620\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,13]]},"references-count":53,"alternative-id":["10.3389\/fimmu.2023.1268620"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1268620","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,13]]},"article-number":"1268620"}}